
Symbiotec Pharmalab plans IPO to boost specialty pharma market
Mumbai: Symbiotec Pharmalab, a global leader in manufacturing corticosteroid and hormone active pharmaceutical ingredients (APIs), is planning an initial public offering (IPO) in the next 12 months at a targeted valuation of about $1 billion, said people …